Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 13 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

23%

3 trials in Phase 3/4

Results Transparency

0%

0 of 11 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
5(38.5%)
Phase 3
3(23.1%)
Phase 1
3(23.1%)
Phase 2
2(15.4%)
13Total
N/A(5)
Phase 3(3)
Phase 1(3)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (13)

Showing 13 of 13 trials
NCT07300202Phase 1Completed

CLINICAL RESEARCH PROTOCOL [A Phase I, Single-arm, Open-label, Dose-escalation Clinical Study to Evaluate the Safety and Tolerability of Orialpha (BD-C) in Healthy Adult Volunteers]

Role: collaborator

NCT05636891Phase 1Completed

Pharmacokinetic/Pharmacodynamic Parameters of NNG-DEPO (Stimus) With Aranesp® (Amgen) in Treatment of Anemia in CKD Patients on Dialysis

Role: collaborator

NCT05585645Phase 3Completed

A Study to Compare Efficacy and Safety of Nanogen's Darbepoetin Alfa With Aranesp® (Amgen) in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis (CKD)

Role: collaborator

NCT06637683Not ApplicableCompleted

Efficacy of LiveSpo COLON as a Supportive Treatment for Inflammatory Bowel Disease (IBD)

Role: collaborator

NCT05999955Not ApplicableCompleted

Safety and Efficacy of DSM 32444 Postbiotic in the Treatment of Acute Rhinosinusitis

Role: collaborator

NCT04695717Phase 3Completed

This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam

Role: collaborator

NCT05301010Phase 3Completed

Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients

Role: collaborator

NCT05301530Phase 1Completed

Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.

Role: collaborator

NCT05082727Phase 2Unknown

Safety and Efficacy of Softgel KOVIR (TD0068) in the Combination Regimen With Background Treatment in COVID-19 Patients (KOVIR)

Role: collaborator

NCT05140720Not ApplicableUnknown

Assess the Safety and Immunogenicity of PNEUMOSIL® Vaccine in Healthy Vietnamese Children, 6 Weeks to 24 Months of Age

Role: collaborator

NCT03931239Not ApplicableCompleted

The Transparent Safety Study of the 5 in 1 (DTwP-rHepB-Hib) Combination Vaccine Produced by the Indian Serine Institute in Children of Viet Nam Healthy From 6 to 12 Weeks of Age in a 3-dose Regimen, the Interval Between Doses is 4 Weeks

Role: collaborator

NCT03717714Not ApplicableCompleted

Polycan in Combination With Glucosamine for Treatment of Knee Osteoarthritis

Role: lead

NCT02798159Phase 2Completed

Safety and Efficacy of TD0025 (Rocket1h) for Treatment of Erectile Dysfunction

Role: lead

All 13 trials loaded